A phase I study with CRx-026, a novel dual action agent, in patients (pts) with advanced solid tumors.

被引：0
|
作者：
von Hoff, DD
Gordon, M
Turner, J
White, E
Nichols, MJ
Elliott, PJ
Mendelson, D
机构：
[1] Arizona Canc Ctr, Scottsdale, AZ USA
[2] CombinatoRx Inc, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：210S / 210S
页数：1
相关论文
共 50 条
  • [1] Phase I and pharmacokinetic (PK) study of a novel cytotoxic agent, PNU-159548, in patients (pts) with solid tumors.
    Maja, JAD
    Wortelboer, M
    van der Gaast, A
    Colajori, E
    Valota, O
    Fiorentini, F
    Verweij, J
    Sessa, C
    CLINICAL CANCER RESEARCH, 1999, 5 : 3729S - 3729S
  • [2] A phase I study of MK-2206 in combination with lapatinib in patients (pts) with advanced solid tumors.
    Wisinski, Kari Braun
    Tevaarwerk, Amye
    Bell, Maria
    Burkard, Mark E.
    Eickhoff, Jens C.
    Wilding, George
    LoConte, Noelle K.
    Traynor, Anne M.
    Hoang, Tien
    Heideman, Jennifer
    Kolesar, Jill
    Liu, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors.
    Rudin, C. M.
    Jimeno, A.
    Miller, W. H.
    Eigl, B. J.
    Gettinger, S. N.
    Chang, A. L. S.
    Faia, K.
    Sweeney, J.
    Loewen, G.
    Ross, R. W.
    Weiss, G. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Phase I and pharmacologic study of the vascular disrupting agent ombrabulin (Ob) combined with docetaxel (D) in patients (pts) with advanced solid tumors.
    Tresca, P.
    Tosi, D.
    van Doorn, L.
    Fontaine, H.
    Gaast, A. V.
    Veyrat-Follet, C.
    Oprea, C.
    Dieras, V.
    Eskens, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of MN-029, a novel vascular disrupting agent (VDA), in patients (pts) with advanced solid tumors.
    Ricart, A. D.
    Cooney, M.
    Sarantopoulos, J.
    Brell, J.
    Locke, K. W.
    Gammans, R. E.
    Medina, G.
    Zambito, A.
    Tolcher, A. W.
    Remick, S. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 144S - 144S
  • [6] A phase I QTc study of tivozanib in patients with advanced solid tumors.
    Chadha, Manpreet Kaur
    Infante, Jeffrey R.
    Cotreau, Monette M.
    Jacobson, Lindsey
    Strahs, Andrew Louis
    Slichenmyer, William
    Vargo, Dennis
    Moore, Kathleen N.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [7] Phase I study of sapacitabine and seliciclib in patients with advanced solid tumors.
    Tolaney, Sara M.
    Hilton, John Frederick
    Cleary, James M.
    Gandhi, Leena
    Kwak, Eunice Lee
    Clark, Jeffrey W.
    Wolanski, Andrew
    Bell, Tracy Demeo
    Rodig, Scott J.
    Chiao, Judy H.
    Blake, David
    Shapiro, Geoffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors.
    El-Khoueiry, Anthony B.
    Ning, Yan
    Yang, Dongyun
    Cole, Sarah
    Kahn, Michael
    Zoghbi, Marwan
    Berg, Jennifer
    Fujimori, Masamoto
    Inada, Tetsuhi
    Kouji, Hiroyuki
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] A phase I study of afatinib combined with carboplatin or carboplatin plus paclitaxel in patients (pts) with advanced solid tumors.
    Gao, Fangfei
    O'Brien, Mary
    Sarker, Debashis
    Bhosle, Jaishree
    Yap, Timothy Anthony
    Uttenreuther-Fischer, Martina Maria
    Pemberton, Karine
    Goeldner, Rainer-Georg
    Wiebe, Sabrina
    De Bono, Johann S.
    Spicer, James F.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Phase I study of LHC165 ± spartalizumab (PDR001) in patients (pts) with advanced solid tumors.
    Curigliano, Giuseppe
    Martin Jimenez, Miguel
    Shimizu, Toshio
    Keam, Bhumsuk
    Meric-Bernstam, Funda
    Rutten, Annemie
    Glaspy, John
    Parikh, Nehal S.
    Ising, Mary
    Hassounah, Nadia
    Wu, Jincheng
    Xu, Kun
    Choudhry, Somesh
    Garralda, Elena
    CANCER RESEARCH, 2021, 81 (13)
12345